Therapeutics: β-catenin (CTNNB1); wingless-type MMTV integration site family member 3A (WNT3A); 7-dehydrocholesterol reductase (DHCR7); glycogen synthase kinase

Other

INDICATION: Genetic disorders

In vitro studies suggest activating Wnt/CTNNB1 signaling could help treat microcephaly associated with Smith-Lemli-Opitz

Read the full 170 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE